How to Manage IBS-M Without Overcorrecting

If you have IBS with mixed bowel habits, the single most useful shift is to stop managing the label and start managing the week in front of you. IBS-M is not a third condition with its own playbook. It is a description of how your bowel habit has been distributed lately, and that distribution moves. What does not move is the small set of treatments with evidence across all subtypes, and the fact that most of the drugs written up in IBS articles were tested in people with constipation only or diarrhoea only.

That evidence gap is the real story of IBS-M, and almost no page ranking for this keyword mentions it. The other thing those pages get wrong is the swing itself. They describe IBS-M as alternating between constipation and diarrhoea, which sounds tidy. When somebody actually measured it with daily diaries over a year, the direct swing between constipated and diarrhoeal patterns turned out to be the least common transition of all.

The short answer: treat the week, not the label

Pick a direction for the current stretch, use the smallest intervention that moves stool form toward the middle of the Bristol scale, change one thing at a time, and give it long enough to judge. Keep a stable background of the things that help regardless of direction. That is the whole strategy, and everything below is the detail behind it.

The reason to work this way rather than from a list of IBS-M remedies is that your bowel habit is a moving target and the interventions are not instant. If you treat Tuesday's constipation with something that acts on Thursday, and Thursday is a loose day anyway, you will conclude the product "caused diarrhoea" and never try it again. People in r/ibs describe exactly this loop: taking an antidiarrhoeal to get through a bad morning and then paying for it with several days of constipation (r/ibs thread on what helped most). Two separate commenters in that thread described the same trade, one of them saying they take half a tablet and then cannot go for days.

The swing is partly the condition. It is also partly what we do to it.

What IBS-M actually means, and what it does not

Under Rome IV, subtype is decided using only the days when your bowel movements were abnormal. If at least a quarter of those abnormal days were hard or lumpy and at least a quarter were loose or watery, that is IBS-M (Mearin 2016). Normal days are excluded from the arithmetic entirely, which is the single most misunderstood part of the rule, and it is why the Rome IV criteria classify roughly half as many people as having IBS as Rome III did, at 4.6% versus 9.0% of adults in a survey of 5,931 people across three countries (Palsson 2020). Our post on the difference between IBS-D and IBS-C works through that calculation in full, so this article will not repeat it.

Three things worth stating plainly, because the ranking pages tend to treat IBS-M as an afterthought:

It is not a small group. In the Rome Foundation Global Epidemiology Study, which surveyed 54,127 people across 26 countries and identified 2,195 with IBS, IBS-M accounted for 712 of them, exactly level with IBS-C (Hod 2026). In a clinic-based cross-sectional study of 4,862 people with Rome IV IBS, IBS-M was the largest subtype at 46.8% (Pereyra 2024).

It is not a milder version of the other two. In that same clinic study, the IBS-M group had the highest mean symptom severity score on the IBS-SSS at 320, compared with 310 for IBS-D and 290 for IBS-C, and the highest mean depression questionnaire score. Both are cross-sectional associations, and a clinic population is more severe than a community one, so do not read this as a prediction about you.

It is not a diagnosis of exclusion. People sometimes assume "mixed" means the clinician could not decide. It is a defined category with a stated rule. The genuinely leftover category is IBS-U, for people who meet the criteria for IBS but whose abnormal days do not reach the thresholds for any of the three patterns.

Does IBS-M really swing from constipated to loose?

This is the tidy mechanism every ranking page teaches: IBS-M means you alternate between constipation and diarrhoea. Someone tested it, and the result is more interesting than the slogan.

Drossman and colleagues followed 317 women with IBS entering a treatment trial, using two-week daily diary cards of stool frequency and consistency at baseline and then at four three-month intervals across a year. The proportion of people in each subtype stayed roughly constant over the year, which is what you would expect. But more than 75% of individuals moved to one of the other two subtypes at least once. IBS-M was the least stable group, with 50% moving out of it within 12 weeks. The transitions were not symmetrical: people moved between IBS-M and IBS-C far more often than between IBS-D and IBS-M, and only 29% ever switched between IBS-D and IBS-C across the entire year (Drossman 2005).

Read that again, because it undercuts the standard description. The dramatic constipated-to-diarrhoeal flip that gives IBS-M its reputation was the rarest movement in the dataset. The common drift was between mixed and constipated.

That does not mean fast fluctuation is imaginary. A separate analysis of 1,102 people with IBS set out to define the alternating subtype and found that stool consistency was the most specific criterion for it, and that people in the alternating group reported rapid fluctuations in bowel habit with short flares and remissions, along with a higher prevalence of psychological and extra-intestinal symptoms than IBS-C or IBS-D (Tillisch 2005). Quality of life scores did not differ between subtypes.

A third study asked how long you need to watch before the label means anything. In 126 people with Rome III IBS keeping Bristol scale records for ten weeks, only 18% to 35% had the same subtype in every single week, but 82% to 98% had the same subtype for at least 60% of the time, and two weeks of data was better than one at identifying someone's predominant subtype (Engsbro 2012).

Put those three together and you get a usable picture. Week to week you probably have a predominant direction. Month to month that direction drifts, most often toward or away from constipation. Day to day it can feel like noise.

This matches what people describe. In an r/ibs thread asking people with alternating type whether their symptoms are chaotic, the replies split cleanly: several described runs lasting days or weeks, with one person saying they can go once a week for a month and then have a week of going several times a day, while others described both patterns inside a single evening (r/ibs thread on chaotic symptoms). Both descriptions are consistent with the research. The difference is the timescale you happen to be looking at.

Why one bowel movement can run half the Bristol scale

The most-asked IBS-M question on Reddit is not about treatment at all. It is about a single bowel movement that starts with hard pellets, becomes smooth, and ends in pieces that fall apart. A thread asking exactly that drew 78 comments and dozens of people saying they thought they were the only one (r/ibs thread on the Bristol scale in one sitting).

The explanation is mundane. Stool form is essentially a readout of how long material has been sitting in your colon having water drawn out of it. When 32 healthy volunteers had regional gut transit measured scintigraphically and with radio-opaque markers, hard stools correlated significantly with slow colonic transit and loose stools with fast colonic transit, while stool form could not be related to gastric emptying or small bowel transit at all (Degen 1996). The Bristol scale itself was validated against whole-gut transit time in 66 volunteers whose transit was deliberately sped up and slowed down, and change in stool form tracked change in transit better than stool frequency or stool weight did (Lewis 1997).

So a single defecation is not one uniform substance. It is a column of material with a gradient of residence times. The oldest and most dehydrated part is at the front. What follows had less time in contact with the colonic wall. If you have gone a couple of days without passing anything, the front end can be genuinely hard while the material queued behind it is barely processed.

Two practical consequences follow, and one important caveat.

First, this pattern is not itself evidence of anything alarming. It is what you would predict from the physiology. It is also why the "predominant stool form" question in Rome IV is answered per bowel movement rather than per fragment. If you are logging, record the form that best represents the movement as a whole, and be consistent about how you decide. Our guide to what Bristol stool type 6 means covers the scale itself.

Second, when the pattern is reversed, with watery stool first and hard pieces afterwards, that can reflect liquid passing around retained stool. Several people in those threads described being told as much by their clinician. It is worth mentioning to a doctor if it is a new and persistent pattern, because the management of retained stool is different from the management of fast transit.

The caveat: none of this applies to blood. Bleeding, unexplained weight loss, symptoms that wake you at night, fever, anaemia, a persistent change in bowel habit starting after age 50, or a family history of bowel cancer or inflammatory bowel disease are red flags that sit outside the IBS conversation entirely, and they need a doctor promptly (NICE CG61).

The evidence problem nobody tells you about

Here is the part that changes how you should read every other IBS article. The drug trials that built the modern IBS evidence base mostly recruited by subtype, and IBS-M was frequently not the subtype they recruited.

Look at what the pivotal trials actually enrolled:

The pattern is hard to miss. The treatments with the most impressive-looking numbers are the ones least likely to have been tested on people with your bowel pattern, and the treatments tested across all subtypes are the unglamorous ones.

The nearest thing to an IBS-M-inclusive drug analysis is that network meta-analysis of licensed therapies, which opens by noting that over half of patients with IBS have either diarrhoea or a mixed stool pattern, and which pooled 18 randomised trials of alosetron, ramosetron, rifaximin and eluxadoline in adults with IBS-D or IBS-M. All were superior to placebo at 12 weeks on the endpoint the US regulator recommends for IBS trials, with alosetron ranked first on the composite endpoint (Black 2020). What the abstract does not give, and what I did not verify in the supplementary material, is a separate effect estimate for the IBS-M participants. Availability and licensing of these drugs differ by country, and I have not checked the current regulatory status of each one.

This is not a reason for despair, and it is not a reason to assume subtype-specific drugs cannot help you. It is a reason to be sceptical of confident claims. It also explains something people with IBS-M find baffling: why two gastroenterologists can give opposite advice with equal certainty. Neither of them has a trial that answers the question.

What works regardless of subtype

Start here, because this is where the evidence is not conditional on which way your bowel is currently leaning.

Soluble fibre. A meta-analysis of 14 randomised trials in 906 people with IBS found a significant benefit with a number needed to treat of 10 overall, and when the analysis was split by fibre type the benefit was confined to soluble fibre, number needed to treat 7, with no effect for bran (Moayyedi 2014). A primary-care trial of 275 patients found psyllium beat placebo in the first and second months, while bran only separated from placebo in month three and not robustly (Bijkerk 2009). NICE's guidance reflects this, recommending against insoluble fibre such as bran and, where fibre is increased, that it be soluble (NICE CG61).

That is a genuinely useful finding for mixed habits, because soluble fibre is the rare lever that is not directional. The practical caveat that shows up constantly in patient reports and rarely in the articles is that the first week or two can bring more gas. One person in the r/ibs thread described starting at half a teaspoon on their doctor's advice and working up. Whether and how to do that is a conversation with your GP or pharmacist, not something to copy from a thread.

Antispasmodics and peppermint oil. A network meta-analysis of traditional IBS therapies ranked peppermint oil first for global symptoms, ahead of antispasmodics and gut-brain neuromodulators (Black 2020). Read the individual trial evidence before getting excited, though: a well-designed double-blind trial of 190 people with Rome IV IBS found that peppermint oil did not meet its primary endpoint of abdominal pain response, with 46.8% responding on small-intestinal-release capsules versus placebo at a non-significant p value of 0.17 (Weerts 2020). A trial missing its primary endpoint is a miss, whatever the pooled ranking says.

Gut-brain neuromodulators. The ATLANTIS trial is the most relevant recent trial for IBS-M specifically, because it enrolled Rome IV IBS of any subtype in 55 English general practices, in people still symptomatic despite dietary changes and first-line therapies, and used patient-led titration of low-dose amitriptyline against symptoms and tolerability over six months (Ford 2023). This is a prescription decision for your GP, and the drug is not licensed for IBS in the UK, which NICE states explicitly. It is listed here because it is one of the few good trials whose entry criteria did not exclude you.

Psychological therapy. A network meta-analysis of 41 randomised trials in 4,072 people found that self-administered or minimal-contact CBT, face-to-face CBT and gut-directed hypnotherapy all reduced the risk of remaining symptomatic, with relative risks between 0.61 and 0.67 (Black 2020). Trials in IBS are hard to blind, and these were no exception, so treat the effect sizes as optimistic. Both the ACG guideline and the BSG guideline recommend gut-directed psychological therapy for global IBS symptoms (Lacy 2021, Vasant 2021).

Physical activity. In a randomised trial of 102 people with IBS, those instructed by a physiotherapist to increase physical activity improved by 51 points on the IBS-SSS versus 5 points in the control group, and fewer of them deteriorated over the study period (Johannesson 2011). It was not blinded and could not be, so some of that is expectation. It is still the cheapest thing on this list.

Treating the constipation without tipping into diarrhoea

This is the question the queue row was built around, and the answer is a method rather than a product.

The governing principle is in the NICE guideline and it is worth quoting closely: people with IBS should be advised how to adjust their doses of laxative or antimotility agent according to clinical response, and the dose should be titrated according to stool consistency, aiming for a soft, well-formed stool corresponding to Bristol type 4 (NICE CG61). Our post on what to take to a clinician covers why that target matters when you hand over a record.

Titrating against stool form rather than against how desperate you feel is the whole trick, and it is where most of the ping-pong comes from. Four failure modes account for most of it:

Dosing for the worst day. If you take an amount calibrated to the day you had not gone in four days, and you take it on a day when transit has already started moving, you will overshoot. The overshoot then prompts the opposite correction.

Stacking. Two products from different classes at once, or a product plus a large fibre increase plus a new supplement, all started in the same week. When the result is loose stool you cannot tell which one did it, and you usually drop the one that was helping.

Judging too early. Products acting on colonic water and transit do not report back the same day. Judging on a single bowel movement is how you conclude a product "does nothing" or "causes diarrhoea", when what you actually observed was one point on a noisy series.

Not knowing what the evidence promises. The trial of macrogol plus electrolytes in IBS-C is instructive here. Over four weeks in 139 patients it significantly increased spontaneous bowel movements versus placebo and improved stool consistency and straining. But on abdominal discomfort and pain, although the score improved from run-in, there was no difference versus placebo (Chapman 2013). An osmotic laxative is a transit intervention, not a pain intervention. If you expect it to fix cramping and it does not, that is the product working as tested, not failing.

NICE also advises discouraging lactulose specifically in IBS, while considering other laxatives for constipation (NICE CG61). Nothing in this article is a recommendation to start, stop or change anything you take. Take the method to your GP or pharmacist and let them pick the product.

The antidiarrhoeal trap that creates the swing

The same titration principle applies from the other direction, and here the overcorrection is more visible because the rebound is more memorable.

NICE names loperamide as the first-choice antimotility agent for diarrhoea in IBS, and the same titration-to-stool-form advice applies to it (NICE CG61). In practice, the way people describe using it is nothing like titration. It gets used as a rescue before an event or a commute, at whatever amount worked last time, on a day when the underlying transit may already be normalising. Multiple commenters in the r/ibs thread described precisely that trade and the days of constipation that followed.

There is a mechanistic reason this is so effective at manufacturing a mixed pattern. Loperamide was the drug used to slow transit in the study that validated the Bristol scale, and it reliably shifted stool form, frequency and output in the expected direction in healthy volunteers (Lewis 1997). It works. That is the problem. A potent transit brake applied to an already-variable system produces a bigger downstream swing than the original symptom did, and then the constipation gets treated, and the cycle has a rhythm.

Nobody has run a trial of "IBS-M managed by symptom-chasing versus IBS-M managed by titration", so I cannot tell you how much of the average person's alternation is iatrogenic. What I can say is that the swing is partly under your control at the point where you decide how much to correct, and that titrating against stool form is what the guideline actually asks for.

Diet in IBS-M: what the evidence supports, and what it does not

The ACG guideline recommends a limited trial of a low FODMAP diet in IBS to improve global symptoms (Lacy 2021). That recommendation is for IBS, not for IBS-M, and the trials behind it recruited IBS broadly. The landmark crossover trial provided almost all food to 30 patients with IBS and 8 controls for 21 days per arm and found overall gastrointestinal symptom scores of 22.8 mm on the low FODMAP arm versus 44.9 mm on a typical Australian diet (Halmos 2014). That is a real effect, in a highly controlled feeding study that bears little resemblance to doing it yourself.

The comparison that gets left out of most IBS-M articles is the one that matters most for a first attempt. A multicentre Swedish trial randomised 75 people with Rome III IBS to either a low FODMAP diet or traditional IBS dietary advice, the kind that emphasises regular meal patterns, avoiding large meals, and reducing fat, insoluble fibre, caffeine and gas-producing foods. Symptom severity fell significantly in both groups, with no significant difference between them (Bohn 2015). For someone with a moving bowel habit and limited energy, the less restrictive route being roughly as good is worth knowing before you start weighing portions.

If you do go the FODMAP route, both NICE and the guidelines frame it as a short, structured process delivered by someone with expertise in dietary management, not as a way of eating (NICE CG61). The reintroduction phase is the point of the exercise, and we cover how long to stay on it and how to reintroduce foods separately.

Two IBS-M-specific dietary points do deserve their own attention.

Polyols can flip a constipated stretch. A recurring report in r/ibs from people who consider themselves usually constipated is that sorbitol or mannitol reliably produces a diarrhoea day. Sugar alcohols are poorly absorbed in the small intestine, so they draw water osmotically and are fermented in the colon. NICE's general dietary advice specifically tells people with diarrhoea to avoid sorbitol, naming sugar-free sweets, chewing gum and some diabetic and slimming products (NICE CG61). Our sorbitol guide covers the dose relationship and where it hides, including in medicines. If your logs show a loose day that keeps landing a day after a particular product, that is worth testing deliberately rather than guessing.

Fibre is a review, not an increase. NICE's wording is that healthcare professionals should review fibre intake and adjust it, "usually reducing it", while monitoring the effect (NICE CG61). This is the opposite of the standard advice people with constipation receive. In mixed habits, where insoluble fibre may worsen the loose stretches without reliably helping the hard ones, the review framing is more honest than "eat more fibre".

A word on what happens during a bad patch: reaching for a shorter and shorter list of safe foods is common, and the restriction tends to persist after the bad patch ends. What to eat during an IBS flare goes into that, and into why a flare is the worst possible time to try to learn a new trigger.

When "mixed" is actually a different problem

Some of what gets labelled IBS-M is not a transit problem at all, and it will not respond to transit treatments. Three patterns are worth raising with a clinician.

Difficult evacuation rather than slow transit. If your dominant experience is straining, a sense of blockage, incomplete emptying, going repeatedly in a short window with less coming out each time, or needing to help manually, the relevant question is how the pelvic floor and anal sphincter behave during defecation rather than how fast the colon is moving. Dyssynergic defecation is defined by both symptoms of difficult defecation and objective evidence of dyssynergia on testing, and the Rome diagnostic framework lists anorectal manometry, the balloon expulsion test and defecography among the evaluations (Rao 2026). It matters because the treatment is different: in a randomised trial of 77 people with chronic constipation and dyssynergic defecation, biofeedback corrected dyssynergia, reduced balloon expulsion time and increased complete spontaneous bowel movements more than sham feedback or standard therapy of diet, exercise and laxatives (Rao 2007). If the retained stool from that pattern then produces looser material behind it, the whole thing can read as alternating when it is not.

The volume of people describing this is striking. An r/ibs thread titled simply "incomplete bowel movements that never end" ran to nearly 200 comments (r/ibs thread on incomplete evacuation). NICE also notes that incomplete evacuation and rectal hypersensitivity are commonly reported by people presenting with IBS symptoms, and that about 20% of people with faecal incontinence only disclose it if asked (NICE CG61).

Bile acid diarrhoea. If the loose half of your pattern is watery, urgent and often early in the day, this is worth asking about. A systematic review of 18 studies and 1,223 patients presenting with IBS-D type symptoms found that 10% had severe bile acid malabsorption on SeHCAT scanning, 32% had moderate malabsorption and 26% had mild, with response to a bile acid binder tracking the severity of malabsorption (Wedlake 2009). The authors argued that international IBS guidelines needed revising so clinicians would consider it. That review looked at IBS-D populations rather than IBS-M, so it does not tell you the prevalence in mixed habits, and testing availability varies a great deal by country.

Everything IBS is not. The ACG guideline suggests serologic testing for coeliac disease in people with IBS and diarrhoea symptoms, and faecal calprotectin in suspected IBS with diarrhoea to rule out inflammatory bowel disease (Lacy 2021). NICE lists a full blood count, inflammatory markers and coeliac antibodies as the tests to exclude other diagnoses in people meeting the criteria (NICE CG61). If you have never had those, that is a reasonable thing to raise. Our comparison of SIBO and IBS symptoms covers another look-alike and why the testing there is contested.

What to track when your pattern keeps moving

Tracking matters more in IBS-M than in either of the other subtypes, for a specific reason: you are the person whose label is least stable, so you are the person whose memory is least reliable about it. Drossman's cohort was diaried precisely because recalled bowel habit could not be trusted over a year.

A workable minimum, and no more than that:

1. Date, time and Bristol type for every bowel movement. This is the one non-negotiable field. Form, not frequency, is what tracks transit (Lewis 1997).
2. Whether the day was abnormal at all. Rome IV only counts abnormal days, so a normal day needs to be marked normal rather than left blank.
3. Urgency and incomplete emptying as separate flags. These are what distinguish a possible evacuation problem from a transit problem, and they are what a clinician can act on.
4. Anything you took, and when. Not to prove it worked, but so that next month you can tell whether the loose stretch followed a correction.
5. Two weeks minimum before you draw any conclusion. Two-week windows outperformed one-week windows at identifying a predominant subtype (Engsbro 2012).

Then do the arithmetic rather than eyeballing it. Count the abnormal days. Of those, what fraction were type 1 or 2, and what fraction were type 6 or 7? That ratio is your subtype for that window, and watching it move across three or four windows tells you something a single appointment cannot.

If you would rather not keep this on paper, Clairop logs meals and symptoms in seconds by voice or barcode and surfaces likely triggers with the delay window they were seen at, which is the part that is hard to do by hand when the pattern moves. Our guide to keeping a food diary for IBS covers the mechanics either way, including why informal trigger hunting throws up so many false positives.

A worked example: four weeks of logs

Here is what the arithmetic looks like on a made-up but realistic month. This is an illustration of the method, not a case report.

Week 1. Nine bowel movements over seven days. Four days recorded as normal. Of the five abnormal days, three were type 2 and two were type 6. Abnormal-day split: 60% hard, 40% loose. Predominant direction this week: constipated-leaning mixed.

Week 2. Started a soluble fibre supplement at the start of the week, nothing else changed. Eleven bowel movements. Three normal days. Of four abnormal days, two type 2 and two type 6. Gas noticeably worse on days two to four, then settling. Split: 50/50. Nothing conclusive yet, and the gas is the expected early pattern, so the sensible move is to hold rather than to add or drop anything.

Week 3. Twelve bowel movements. Five normal days. Of two abnormal days, one type 3 and one type 6. Abnormal days have halved. Split now mostly loose, but on a much smaller denominator, which is the point that trips people up: a smaller proportion of a smaller number is not a worse week.

Week 4. Two very loose days midweek, both following an evening with sugar-free mints. Everything else stable. Nine bowel movements, five normal days, four abnormal, three of them type 6.

What the month tells you: the fibre change plausibly reduced the number of abnormal days overall, which is a better outcome measure than the subtype ratio. The week 4 loose days have an obvious candidate that is worth testing deliberately on a quiet week rather than assuming. And the subtype label moved from constipated-leaning to loose-leaning across four weeks without anything dramatic happening, which is exactly the instability the literature describes.

What the month does not tell you: whether the fibre caused the improvement. One person, one arm, no control, and IBS symptoms regress toward the mean anyway. Our post on why safe foods sometimes trigger symptoms explains why single observations mislead so consistently.

Myths about IBS-M worth retiring

"IBS-M means you flip between constipation and diarrhoea." The direct flip between IBS-D and IBS-C was the least common transition in the one study that diaried it for a year, at 29% of people over twelve months. The common drift was between mixed and constipated (Drossman 2005).

"Mixed means the doctor could not decide." It is a defined Rome IV category with a stated threshold on both sides, and it was the largest subtype in a 4,862-patient clinic series (Pereyra 2024).

"There is an IBS-M diet." There is no diet trial recruiting IBS-M specifically that I found. The dietary evidence is for IBS broadly, and the one head-to-head trial of low FODMAP against traditional dietary advice found no significant difference between them (Bohn 2015).

"Passing several Bristol types in one sitting means something is seriously wrong." It follows from stool form being a readout of colonic residence time (Degen 1996). Bleeding, weight loss and night-time symptoms are the things that need urgent attention, not a variable-consistency bowel movement.

"Fibre is fibre." Bran showed no benefit in the pooled analysis while soluble fibre did, and NICE advises discouraging insoluble fibre in IBS (Moayyedi 2014, NICE CG61).

"If a drug is approved for IBS, it was tested in people like me." Often not. The secretagogue evidence base is entirely IBS-C (Black 2018), and the large eluxadoline programme was IBS-D only (Lembo 2016).

"Peppermint oil is proven for IBS." It ranked first in a pooled network analysis, and then missed its primary endpoint in a 190-patient double-blind trial (Weerts 2020). Both of those are true at once.

"IBS-M is milder because it balances out." In the clinic series it carried the highest mean symptom severity score and the highest depression questionnaire score of the three subtypes (Pereyra 2024). Those are associations in a referral population, not a prediction about any individual, but it is not a milder label.

When to see a doctor

See a doctor promptly if you have any of these, regardless of what your usual pattern looks like: blood in your stool or black tarry stools, unexplained weight loss, symptoms that wake you from sleep, fever, signs of anaemia such as unusual breathlessness or fatigue, a persistent change in bowel habit that started after age 50, a family history of bowel cancer or inflammatory bowel disease, or an abdominal or rectal mass. These sit outside the IBS conversation and need investigating (NICE CG61).

Also worth a non-urgent appointment:

• You have never had the basic tests. Full blood count, inflammatory markers and coeliac antibodies are the standard exclusions, and faecal calprotectin is suggested where diarrhoea is part of the picture (Lacy 2021, NICE CG61).
• Straining and incomplete emptying dominate. Ask specifically whether anorectal function testing is appropriate, because that route has its own treatment (Rao 2026).
• The loose half is watery, urgent and clustered early in the day. Ask whether bile acid testing is available where you are (Wedlake 2009).
• You have been titrating for months and the swing is not narrowing. That is the point at which guidelines talk about second-line options and about gut-directed psychological therapy (Vasant 2021).
• Any faecal incontinence. NICE notes most people do not mention it unless asked, and it changes what a clinician does next.

If you have previously been told you have IBS and something about the pattern has genuinely changed, that is a reason to be re-assessed rather than to adjust what you take. How do I know if my IBS is flaring up covers the difference between a bad stretch and a change worth re-investigating.

The short version

IBS-M is a description of a distribution, and the distribution moves. The research says the movement is usually slower and less dramatic than the word "alternating" implies, that the mixed label is the least stable of the three, and that a single bowel movement running half the Bristol scale is a predictable consequence of stool form tracking colonic residence time.

The management follows from that. Look at two-week windows rather than days. Do the abnormal-day arithmetic rather than trusting your memory. Lean on the interventions whose trials did not exclude you, which are the unglamorous ones. Titrate against stool form rather than against how bad you feel, because that is what the guideline asks for and because overcorrection is the one part of the swing you have direct control over. And when straining and incomplete emptying dominate, or the loose half is watery and urgent, raise the possibility that what is being managed as mixed IBS is something with its own test and its own treatment.

The honest bottom line is that the field has not studied you as carefully as it has studied people at either end. Knowing that is more useful than another list of foods.